KR101598679B1 - mGlu2 수용체 효능제로서의 비시클로(3.1.0)헥산-2,6-디카르복실산 유도체 - Google Patents
mGlu2 수용체 효능제로서의 비시클로(3.1.0)헥산-2,6-디카르복실산 유도체 Download PDFInfo
- Publication number
- KR101598679B1 KR101598679B1 KR1020137033028A KR20137033028A KR101598679B1 KR 101598679 B1 KR101598679 B1 KR 101598679B1 KR 1020137033028 A KR1020137033028 A KR 1020137033028A KR 20137033028 A KR20137033028 A KR 20137033028A KR 101598679 B1 KR101598679 B1 KR 101598679B1
- Authority
- KR
- South Korea
- Prior art keywords
- hydrogen
- compound
- hexane
- alkyl
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 Cc1nnc(*)[n]1 Chemical compound Cc1nnc(*)[n]1 0.000 description 5
- LFKDJXLFVYVEFG-UHFFFAOYSA-N CC(C)(C)OC(N)=O Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 2
- GVSNQMFKEPBIOY-UHFFFAOYSA-N Cc1n[nH]nc1 Chemical compound Cc1n[nH]nc1 GVSNQMFKEPBIOY-UHFFFAOYSA-N 0.000 description 2
- VZLMXVGSPYFIEO-SWSUZQIZSA-N CC(C)(C)OC(NC/C(/N)=[O]/OC([C@H](C[C@@H]([C@H]12)Sc3nnc[nH]3)[C@@H]1[C@H]2C(O)=O)=O)=O Chemical compound CC(C)(C)OC(NC/C(/N)=[O]/OC([C@H](C[C@@H]([C@H]12)Sc3nnc[nH]3)[C@@H]1[C@H]2C(O)=O)=O)=O VZLMXVGSPYFIEO-SWSUZQIZSA-N 0.000 description 1
- JCZVQGLZEAGPRJ-XOCIWYINSA-N CC(C)(C)OC([C@@H]([C@@H]1[C@@H](C2)Br)[C@H]1[C@@]2(C(OC(C)(C)C)=O)NC(OC(C)(C)C)=O)=O Chemical compound CC(C)(C)OC([C@@H]([C@@H]1[C@@H](C2)Br)[C@H]1[C@@]2(C(OC(C)(C)C)=O)NC(OC(C)(C)C)=O)=O JCZVQGLZEAGPRJ-XOCIWYINSA-N 0.000 description 1
- HOEGWVKPYDFTSX-RVOOSNJASA-N CCOC([C@@H]([C@@H]1[C@H](C2)Sc3nnc[nH]3)[C@H]1[C@@]2(C(OCC)=O)NC([C@H](C)NC(OC(C)(C)C)=O)=O)=O Chemical compound CCOC([C@@H]([C@@H]1[C@H](C2)Sc3nnc[nH]3)[C@H]1[C@@]2(C(OCC)=O)NC([C@H](C)NC(OC(C)(C)C)=O)=O)=O HOEGWVKPYDFTSX-RVOOSNJASA-N 0.000 description 1
- UOGZHXJOUUECIB-QMGXLNLGSA-N CCOC([C@H]([C@H]1[C@@H](C2)C(O)=O)[C@@H]1[C@H]2Sc1n[nH]cn1)=O Chemical compound CCOC([C@H]([C@H]1[C@@H](C2)C(O)=O)[C@@H]1[C@H]2Sc1n[nH]cn1)=O UOGZHXJOUUECIB-QMGXLNLGSA-N 0.000 description 1
- SGJDFJNXXWQUHX-ZKKRXERASA-N CCOC([C@H]([C@H]1[C@@H](C2)C(OCC)=O)[C@@H]1[C@H]2Sc1n[nH]cn1)=O Chemical compound CCOC([C@H]([C@H]1[C@@H](C2)C(OCC)=O)[C@@H]1[C@H]2Sc1n[nH]cn1)=O SGJDFJNXXWQUHX-ZKKRXERASA-N 0.000 description 1
- OSDBEHZACPQLFE-HPGFDKJQSA-N N[C@@](C[C@@H]([C@H]12)Sc3n[nH]cn3)([C@@H]1[C@H]2C(OCc1cccc(C(F)(F)F)c1)=O)C(OCc1cccc(C(F)(F)F)c1)=O Chemical compound N[C@@](C[C@@H]([C@H]12)Sc3n[nH]cn3)([C@@H]1[C@H]2C(OCc1cccc(C(F)(F)F)c1)=O)C(OCc1cccc(C(F)(F)F)c1)=O OSDBEHZACPQLFE-HPGFDKJQSA-N 0.000 description 1
- RXZDXHKRDHZRKP-NVPUNQSHSA-N N[C@@](C[C@H]([C@H]12)Sc3n[nH]nc3)([C@@H]1[C@H]2C(O)=O)C(O)=O Chemical compound N[C@@](C[C@H]([C@H]12)Sc3n[nH]nc3)([C@@H]1[C@H]2C(O)=O)C(O)=O RXZDXHKRDHZRKP-NVPUNQSHSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11382208 | 2011-06-17 | ||
| EP11382208.4 | 2011-06-17 | ||
| US201161522791P | 2011-08-12 | 2011-08-12 | |
| US61/522,791 | 2011-08-12 | ||
| PCT/US2012/041229 WO2012173850A1 (en) | 2011-06-17 | 2012-06-07 | Bicyclo (3.1.0) hexane- 2, 6 -dicarboxylic acid derivatives as mglu2 receptor agonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20140009568A KR20140009568A (ko) | 2014-01-22 |
| KR101598679B1 true KR101598679B1 (ko) | 2016-02-29 |
Family
ID=47357416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137033028A Active KR101598679B1 (ko) | 2011-06-17 | 2012-06-07 | mGlu2 수용체 효능제로서의 비시클로(3.1.0)헥산-2,6-디카르복실산 유도체 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9296710B2 (https=) |
| EP (1) | EP2721012B1 (https=) |
| JP (1) | JP5945592B2 (https=) |
| KR (1) | KR101598679B1 (https=) |
| CN (1) | CN103596933B (https=) |
| AU (1) | AU2012271024B2 (https=) |
| BR (1) | BR112013031928B1 (https=) |
| CA (1) | CA2836485C (https=) |
| CY (1) | CY1117682T1 (https=) |
| DK (1) | DK2721012T3 (https=) |
| EA (1) | EA023553B1 (https=) |
| ES (1) | ES2587204T3 (https=) |
| HR (1) | HRP20160676T1 (https=) |
| HU (1) | HUE030171T2 (https=) |
| MX (1) | MX2013014802A (https=) |
| PL (1) | PL2721012T3 (https=) |
| PT (1) | PT2721012T (https=) |
| RS (1) | RS54888B1 (https=) |
| SI (1) | SI2721012T1 (https=) |
| WO (1) | WO2012173850A1 (https=) |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993006127A1 (en) | 1991-09-17 | 1993-04-01 | Warner-Lambert Company | Novel amino acid prodrug renin inhibitors |
| US5576323A (en) | 1993-12-03 | 1996-11-19 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
| US5849525A (en) | 1994-03-09 | 1998-12-15 | Brigham And Women's Hospital, Inc. | Compositions corresponding to a proton-coupled peptide transporter and methods of making and using same |
| GB9605429D0 (en) * | 1995-11-16 | 1996-05-15 | Lilly Co Eli | Excitatory amino acid receptor antagonists |
| CN1202167A (zh) | 1995-11-16 | 1998-12-16 | 伊莱利利公司 | 兴奋性的氨基酸衍生物 |
| US5688826A (en) | 1995-11-16 | 1997-11-18 | Eli Lilly And Company | Excitatory amino acid derivatives |
| US5952294A (en) | 1996-07-31 | 1999-09-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptidyl prodrugs and methods of making and using the same |
| ZA983930B (en) | 1997-05-14 | 1999-11-08 | Lilly Co Eli | Excitatory amino acid receptor modulators. |
| ATE236118T1 (de) | 1998-01-28 | 2003-04-15 | Taisho Pharmaceutical Co Ltd | Fluorhaltige aminosäurederivate |
| ATE269293T1 (de) | 1998-08-31 | 2004-07-15 | Taisho Pharmaceutical Co Ltd | 6-fluoro(3.1.0)hexan-derivate |
| US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| AU6785401A (en) | 2000-06-28 | 2002-01-08 | Taisho Pharmaceutical Co Ltd | Novel dicarboxylic acid derivatives |
| EP1351925A1 (en) | 2001-01-11 | 2003-10-15 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
| HUP0400620A3 (en) | 2001-01-11 | 2012-09-28 | Lilly Co Eli | Prodrugs of excitatory amino acids and pharmaceutical compositions containing them and process for preparation the compounds |
| EP1370519A1 (en) * | 2001-02-22 | 2003-12-17 | Eli Lilly And Company | Synthetic excitatory amino acids |
| BR0210391A (pt) | 2001-06-12 | 2004-06-15 | Elan Pharm Inc | Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto |
| CA2471642C (en) | 2001-12-27 | 2011-05-24 | Taisho Pharmaceutical Co., Ltd. | 6-fluorobicyclo[3.1.0]hexane derivatives |
| WO2003084610A1 (en) | 2002-04-03 | 2003-10-16 | Eli Lilly And Company | Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist |
| US20050192273A1 (en) | 2002-04-03 | 2005-09-01 | Johnson Bryan G. | Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist |
| CN100482680C (zh) * | 2002-06-11 | 2009-04-29 | 伊莱利利公司 | 兴奋性氨基酸前药 |
| EP1517915B1 (en) | 2002-06-11 | 2009-01-21 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
| JP4984529B2 (ja) * | 2003-06-26 | 2012-07-25 | 大正製薬株式会社 | ２−アミノビシクロ［３．１．０］ヘキサン−２，６−ジカルボン酸誘導体 |
| CN100582087C (zh) * | 2003-06-26 | 2010-01-20 | 大正制药株式会社 | 2-氨基-双环[3.1.0]己烷-2,6-二甲酸酯衍生物 |
| DK2513085T3 (en) * | 2009-11-18 | 2016-12-05 | Suven Life Sciences Ltd | Alfa4beta2 bicyclic compounds as nicotinic acetylcholine receptor ligands |
| AR079343A1 (es) | 2009-12-21 | 2012-01-18 | Lilly Co Eli | Compuesto de acido 2-amino-4-(4h-1,2,4-triazol-3-ilsulfanil)biciclo[3.1.0]hexano-2,6-dicarboxilico, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un trastorno psiquiatrico |
-
2012
- 2012-06-07 PT PT127297695T patent/PT2721012T/pt unknown
- 2012-06-07 MX MX2013014802A patent/MX2013014802A/es active IP Right Grant
- 2012-06-07 BR BR112013031928-3A patent/BR112013031928B1/pt active IP Right Grant
- 2012-06-07 ES ES12729769.5T patent/ES2587204T3/es active Active
- 2012-06-07 HU HUE12729769A patent/HUE030171T2/en unknown
- 2012-06-07 SI SI201230569A patent/SI2721012T1/sl unknown
- 2012-06-07 RS RS20160491A patent/RS54888B1/sr unknown
- 2012-06-07 US US14/123,768 patent/US9296710B2/en active Active
- 2012-06-07 JP JP2014515878A patent/JP5945592B2/ja active Active
- 2012-06-07 DK DK12729769.5T patent/DK2721012T3/en active
- 2012-06-07 KR KR1020137033028A patent/KR101598679B1/ko active Active
- 2012-06-07 WO PCT/US2012/041229 patent/WO2012173850A1/en not_active Ceased
- 2012-06-07 AU AU2012271024A patent/AU2012271024B2/en active Active
- 2012-06-07 EA EA201391700A patent/EA023553B1/ru not_active IP Right Cessation
- 2012-06-07 CA CA2836485A patent/CA2836485C/en active Active
- 2012-06-07 PL PL12729769T patent/PL2721012T3/pl unknown
- 2012-06-07 HR HRP20160676TT patent/HRP20160676T1/hr unknown
- 2012-06-07 EP EP12729769.5A patent/EP2721012B1/en active Active
- 2012-06-07 CN CN201280029080.2A patent/CN103596933B/zh active Active
-
2016
- 2016-06-24 CY CY20161100570T patent/CY1117682T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT2721012T (pt) | 2016-07-27 |
| CN103596933A (zh) | 2014-02-19 |
| JP2014517035A (ja) | 2014-07-17 |
| PL2721012T3 (pl) | 2017-05-31 |
| AU2012271024B2 (en) | 2015-07-09 |
| KR20140009568A (ko) | 2014-01-22 |
| BR112013031928B1 (pt) | 2022-05-24 |
| DK2721012T3 (en) | 2016-08-15 |
| SI2721012T1 (sl) | 2016-08-31 |
| EP2721012A1 (en) | 2014-04-23 |
| HRP20160676T1 (hr) | 2016-07-15 |
| US20140113944A1 (en) | 2014-04-24 |
| US9296710B2 (en) | 2016-03-29 |
| CY1117682T1 (el) | 2017-05-17 |
| EA201391700A1 (ru) | 2014-04-30 |
| MX2013014802A (es) | 2014-01-24 |
| CA2836485C (en) | 2016-12-13 |
| WO2012173850A1 (en) | 2012-12-20 |
| CN103596933B (zh) | 2016-03-23 |
| ES2587204T3 (es) | 2016-10-21 |
| JP5945592B2 (ja) | 2016-07-05 |
| BR112013031928A2 (pt) | 2016-12-13 |
| AU2012271024A1 (en) | 2013-11-21 |
| EP2721012B1 (en) | 2016-05-25 |
| RS54888B1 (sr) | 2016-10-31 |
| CA2836485A1 (en) | 2012-12-20 |
| EA023553B1 (ru) | 2016-06-30 |
| HUE030171T2 (en) | 2017-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101395356B1 (ko) | Ｍｇｌｕ２ 효능제 | |
| BR112014030743B1 (pt) | Composto inibidor de neprilisina, processo para a preparação do referido composto, composição farmacêutica e uso do referido composto | |
| JP2018199710A (ja) | ネプリライシン阻害剤 | |
| KR20140067048A (ko) | 라이소포스파티드산 수용체 길항제 | |
| KR20140040104A (ko) | 대사 및 염증 질병의 치료에 유용한 아제티딘 유도체 | |
| US12491185B2 (en) | Inhibitors of mPTP | |
| KR101598679B1 (ko) | mGlu2 수용체 효능제로서의 비시클로(3.1.0)헥산-2,6-디카르복실산 유도체 | |
| JP2014517035A5 (https=) | ||
| HK1171228B (en) | Mglu2 agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0105 | International application |
Patent event date: 20131212 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20131212 Comment text: Request for Examination of Application |
|
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20150226 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20151123 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20160223 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20160223 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| FPAY | Annual fee payment |
Payment date: 20181227 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20181227 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20210202 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20220125 Start annual number: 7 End annual number: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20230126 Start annual number: 8 End annual number: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20240215 Start annual number: 9 End annual number: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20250210 Start annual number: 10 End annual number: 10 |